MS ’83, MD ’83, PD ’86, PD ’89
Dr. Molina is Chief Medical Officer at Sutro Biopharma. Previously, he was Vice President, Oncology Scientific Innovation at Janssen R & D (Johnson and Johnson, JNJ). While at JNJ he was responsible for the clinical development and New Drug Application for abiraterone (Zytiga®), which is now approved for metastatic prostate cancer in more than 100 countries. He was Chief Medical Officer/EVP at Cougar Biotechnology, which was acquired by JNJ in 2009. Arturo also worked at IDEC, then Biogen-IDEC, ultimately becoming Head, Oncology Clinical Development. In collaboration with Genentech, he led the clinical Supplemental Biologics License Application (sBLA) filing activities resulting in FDA approval of Rituxan® in two first-line indications in 2006: follicular lymphoma and diffuse B-cell lymphoma.
From 1991-2002, Dr. Molina was a faculty physician in Hematology/Bone Marrow Transplantation and Medical Oncology/Therapeutics Research at the City of Hope (COH) Comprehensive Cancer Center, where he became an Adjunct Professor, member of the COH Medical Group Board of Directors and President-Elect of the COH Medical Staff. Arturo received his MD and MS (Physiology) from Stanford University, and completed residency in Internal Medicine and fellowships in Medical Oncology, Biological Science, and Bone Marrow Transplantation, all at Stanford.
Arturo was an undergraduate at the University of Texas at Austin where he received a BS in Zoology (Honors) and BA in Psychology (High Honors).